Unaudited NAV for November 2022
Arix Bioscience PLC (ARIX)
Unaudited NAV for November 2022
12-Dec-2022 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Arix Bioscience plc
Unaudited NAV for November 2022
LONDON, 12 December 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (“NAV”) of the Company for the date ended 30 November 2022 as follows:
Date
NAV Breakdown
Total NAV
NAV per share
Listed Portfolio
Unlisted Portfolio
Cash
Other Interests
30 November 22
(unaudited)
£41.8m
£57.1m
£130.0m
£1.9m
£230.8m
£1.79
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
ISIN: GB00BD045071 Category Code: NAV TIDM: ARIX LEI Code: 213800OVT3AHQCXNIX43 Sequence No.: 207309 EQS News ID: 1508581
End of Announcement EQS News Service